Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery

NCT ID: NCT02389023

Last Updated: 2018-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

242 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2019-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effectiveness of negative pressure incision management system (Prevena™ Incision Management System (PIMS) or ActiVAC® with the Prevena™ Dressings (Peel and Place™ or Customizable™), KCI) in the prevention of wound complications including surgical site infection (SSI) and non-infectious complications in patients undergoing vascular surgery with groin incisions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Complications such as surgical site infections, deep wound infections, prosthetic graft infections, and non-infections problems such as wound dehiscence continue to cause significant morbidity for patients undergoing arterial reconstruction for peripheral arterial disease. Patients undergoing leg bypass surgery for limb salvage are at particular risk due to their medical problems such as diabetes and renal failure and location of incisions along the groin area. Surgical site infections (SSI) are estimated to occur in 5-40% of patients undergoing arterial bypass for lower extremity arterial occlusive disease. The in-hospital SSI rate is 5% across the Vascular Study Group of New England, a regional quality improvement registry. Factors contributing to wound infections include patient factors such as advanced age and comorbidities such as obesity, diabetes and renal insufficiency and surgical factors including the division of local lymphatics in the groin, placement of a prosthetic graft and inherent difficulty in keeping an incision across the groin crease covered, dry and protected.

Despite the use of standard sterile technique and perioperative preventative antibiotics infections these complications continue to cause patient morbidity. In addition these complications increase the intensity and cost of care with an added estimated expense of $11,000 per incident. New strategies are needed to reduce these complications. Negative pressure wound therapy has the potential to prevent a variety of wound complications. One innovative strategy that has shown promise is the application of the Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing. When compared to surgical dressing with sterile gauze and tape, the Prevena dressing system has the advantages of providing a sterile barrier, reducing tension on the incision, and removing fluid from the incision. Please refer to patient brochure for an illustration and further description of the Prevena dressing system.

Negative pressure wound therapy has been applied for many years to enhance healing of a variety of open wounds including pressure wounds, diabetic ulcers, venous stasis ulcers, open infected surgical to traumatic wounds and burns with variable success. The treatment is based on evenly distributed local negative pressure applied to the wound surface. The open wound is filled with a sponge and covered with an occlusive dressing which is then connected by means of a set of suction tubes to a device which applies negative pressure on the surface of the wound that can be adjusted either cyclically or continuously. The fluid from the wound is collected into a container. The benefits of negative pressure wound therapy have been reported to include removal of infectious material, reduction in edema and improved perfusion to tissue.

The success of negative pressure wound therapy with open wounds has been extrapolated to intact surgical incisions. Recently a negative pressure wound therapy dressing has been developed for use over closed surgical incisions.

The investigators aim to study the ability of a negative pressure wound therapy dressing to prevent wound complications after vascular surgery involving incisions in the groin.

The aim of this study is to compare the Prevena dressing system to standard surgical dressing in patients undergoing leg bypass surgery or femoral endarterectomy with or without patch angioplasty involving the common femoral artery and/or profunda and/or proximal superficial femoral artery. The index groin may have undergone prior procedures (may be inflow or outflow for existing grafts), but the patient must have fully healed from the prior operation. May include patients with concomitant proximal and/or distal peripheral vascular intervention. The patch may be autogenous venous or arterial or prosthetic material such as bovine pericardium, dacron or polytetrafluoroethylene (PTFE) as well as bilateral femoral endartectomies are eligible for enrollment. The right and left groin incision would be randomized to the same dressing which is consistent with routine clinical practice. for vascular disease involving their legs in a multicenter randomized trial. All other aspects of the procedure are the part of standard vascular surgery practice. Patients undergoing vascular surgery with an incision in the groin will be treated with a standard gauze dressing or the Prevena wound management system which will be applied in the operating room and left on the wound for 5-7 days. Follow-up visits to assess the surgical wound are already standard of care. The two groups will be compared based on the primary and secondary endpoints listed in these documents. Quality of life will be compared by a patient survey and a cost analysis will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Artery Disease Critical Limb Ischemia Claudication

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

surgical site infection infrainguinal bypass incisional wound vacuum assisted closure Prevena

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

standard gauze dressing

a standard post-operative dressing consisting of dry gauze and tape will be placed over the surgical site

Group Type OTHER

standard gauze dressing

Intervention Type OTHER

Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care

Prevena Incision Management System

the Prevena™ Incision Management System (PIMS) or ActiVAC® with the PrevenaTM Dressings (Peel and Place™ or Customizable™) will be placed over the surgical site. The Prevena dressing is not considered experimental and has FDA approval for coverage of at risk closed-surgical incisions. The dressing is already in clinical use for vascular surgery bypass operations at the University of Vermont Medical Center.

Group Type OTHER

Prevena Incision Management system

Intervention Type OTHER

The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

standard gauze dressing

Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care

Intervention Type OTHER

Prevena Incision Management system

The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18
2. Patient undergoing vascular surgery that would include a groin incision as a standard part of the operation. Infrainguinal bypass including femoral popliteal/tibial/pedal artery bypass with autogenous or prosthetic conduit.
3. femoral endarterectomy with or without patch angioplasty involving the common femoral artery and/or profunda and/or proximal superficial artery. The index groin may have undergone prior procedures (may be inflow or outflow for existing grafts), but the patient must have fully healed from the prior operation. May include patients with concomitant proximal and/or distal peripheral vascular intervention. The patch may be autogenous venous or arterial or prosthetic material such as bovine pericardium, dacron or polytetrafluoroethylene (PTFE). Bilateral femoral endarterectomies are eligible for enrollment. The right and left groin incision would be randomized to the same dressing which is consistent with routine clinical practice.
4. Willing to comply with protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent.

Exclusion Criteria

1. Any groin incision on index leg within 12 weeks prior to treatment initiation.
2. Infrainguinal bypass without a groin incision including popliteal-tibial or pedal bypass.
3. Supra inguinal procedures such as open or endovascular abdominal aortic aneurysm repair or aorto-femoral/bi-femoral bypass for occlusive disease.
4. Undergoing current chemotherapy or radiation therapy.
5. Pregnancy or lactation.
6. Inability or refusal to provide informed consent.
7. Patients who received an investigational drug for peripheral arterial disease within 4 weeks of screening or who participated in another non-observational clinical trial in the prior 30 days.
8. Surgical incision in the groin without primary closure including previously open or infected wounds.
9. Sensitivity or allergy to silver.
10. Prior enrollment in this randomized controlled trial.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

KCI USA, Inc

INDUSTRY

Sponsor Role collaborator

MaineHealth

OTHER

Sponsor Role collaborator

Brigham and Women's Hospital

OTHER

Sponsor Role collaborator

Beth Israel Deaconess Medical Center

OTHER

Sponsor Role collaborator

Dartmouth-Hitchcock Medical Center

OTHER

Sponsor Role collaborator

University of Vermont Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Daniel Bertges, MD

Vascular Surgeon

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel J Bertges, MD

Role: PRINCIPAL_INVESTIGATOR

University of Vermont Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Maine Medical Center

Portland, Maine, United States

Site Status RECRUITING

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status RECRUITING

Beth Isreal Deaconess Medical Center

Boston, Massachusetts, United States

Site Status RECRUITING

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status RECRUITING

University of Vermont Medical Center

Burlington, Vermont, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Daniel J Bertges, MD

Role: CONTACT

Phone: 802-847-4548

Email: [email protected]

Lisa A Smith, RN

Role: CONTACT

Phone: 802-656-9921

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jens Eldrup-Joregensen, MD

Role: primary

Louis Nguyen, MD

Role: backup

Keith Ozaki, MD

Role: primary

Louis Nguyen, MD

Role: backup

Mark Wyers, MD

Role: primary

Bjoern D Suckow, MD

Role: primary

Wendy H Aarnio, RN

Role: backup

Lisa Smith, RN

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Stewart AH, Eyers PS, Earnshaw JJ. Prevention of infection in peripheral arterial reconstruction: a systematic review and meta-analysis. J Vasc Surg. 2007 Jul;46(1):148-55. doi: 10.1016/j.jvs.2007.02.065.

Reference Type BACKGROUND
PMID: 17606135 (View on PubMed)

Bandyk DF. Vascular surgical site infection: risk factors and preventive measures. Semin Vasc Surg. 2008 Sep;21(3):119-23. doi: 10.1053/j.semvascsurg.2008.05.008.

Reference Type BACKGROUND
PMID: 18774446 (View on PubMed)

Kalish JA, Farber A, Homa K, Trinidad M, Beck A, Davies MG, Kraiss LW, Cronenwett JL; Society for Vascular Surgery Patient Safety Organization Arterial Quality Committee. Factors associated with surgical site infection after lower extremity bypass in the Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI). J Vasc Surg. 2014 Nov;60(5):1238-1246. doi: 10.1016/j.jvs.2014.05.012. Epub 2014 Jun 20.

Reference Type BACKGROUND
PMID: 24953898 (View on PubMed)

Khuri SF, Daley J, Henderson W, Hur K, Demakis J, Aust JB, Chong V, Fabri PJ, Gibbs JO, Grover F, Hammermeister K, Irvin G 3rd, McDonald G, Passaro E Jr, Phillips L, Scamman F, Spencer J, Stremple JF. The Department of Veterans Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. Ann Surg. 1998 Oct;228(4):491-507. doi: 10.1097/00000658-199810000-00006.

Reference Type BACKGROUND
PMID: 9790339 (View on PubMed)

Ozaki CK, Hamdan AD, Barshes NR, Wyers M, Hevelone ND, Belkin M, Nguyen LL. Prospective, randomized, multi-institutional clinical trial of a silver alginate dressing to reduce lower extremity vascular surgery wound complications. J Vasc Surg. 2015 Feb;61(2):419-427.e1. doi: 10.1016/j.jvs.2014.07.034. Epub 2014 Aug 28.

Reference Type BACKGROUND
PMID: 25175629 (View on PubMed)

Nguyen LL, Brahmanandam S, Bandyk DF, Belkin M, Clowes AW, Moneta GL, Conte MS. Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia. J Vasc Surg. 2007 Dec;46(6):1191-1197. doi: 10.1016/j.jvs.2007.07.053.

Reference Type BACKGROUND
PMID: 18154995 (View on PubMed)

Matatov T, Reddy KN, Doucet LD, Zhao CX, Zhang WW. Experience with a new negative pressure incision management system in prevention of groin wound infection in vascular surgery patients. J Vasc Surg. 2013 Mar;57(3):791-5. doi: 10.1016/j.jvs.2012.09.037. Epub 2013 Jan 9.

Reference Type BACKGROUND
PMID: 23312938 (View on PubMed)

Correia RM, Nakano LC, Vasconcelos V, Cristino MA, Flumignan RL. Prevention of infection in peripheral arterial reconstruction of the lower limb. Cochrane Database Syst Rev. 2025 Oct 29;10:CD015022. doi: 10.1002/14651858.CD015022.pub2.

Reference Type DERIVED
PMID: 41159585 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ncbi.nlm.nih.gov/pubmed/18774446

Vascular surgical site infection: risk factors and preventive measures. Semin Vasc Surg. 2008 Sep;21(3):119-23. doi: 10.1053/j.semvascsurg.2008.05.008. Review.

http://www.ncbi.nlm.nih.gov/pubmed/24953898

Factors associated with surgical site infection after lower extremity bypass in the

http://www.ncbi.nlm.nih.gov/pubmed/9790339

The Department of Veterans Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. Ann

http://www.ncbi.nlm.nih.gov/pubmed/25175629

Prospective, randomized, multi-institutional clinical trial of a silver alginate dressing to reduce lower extremity vascular surgery wound complications. J Vasc Surg. 2015 Feb;61(

http://www.ncbi.nlm.nih.gov/pubmed/18154995

Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia. J Vasc

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Journal+of+vascular+surgery%22%5BJour%5D+AND+matatov%5Bauthor%5D&cmd=detailssearch

Experience with a new negative pressure incision management system in prevention of groin wound infection in vascular surgery patients. J Vasc Surg. 2013 Mar;57(3):791-5. doi: 10.1016/j.jvs.2012.09.037. E

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15371

Identifier Type: -

Identifier Source: org_study_id